A company issues shares when warrants are exercised. It is tempting to multiply the number of shares by the exercise price and call the result fresh funding. That calculation works only if the holder pays cash on those terms.
A cashless exercise settles the right through a net number of shares instead. The ownership denominator can grow while the company receives no exercise payment. That distinction matters when a small business needs money for development, manufacturing or ordinary operating bills.
The label alone is insufficient. One warrant may allow cashless exercise only when a resale registration is unavailable. Another may offer it more broadly. A pre-funded warrant has already collected most of its purchase price. Read the cash condition alongside the share count.
Fact: three disclosures with different cash boundaries
Cingulate (Nasdaq: CING) described a warrant covering 1,869,415 common shares in its April 2026 resale prospectus. Full cash exercise would produce approximately $9.4 million. The document also allowed cashless exercise before the associated registration statement became effective. That is a dated contractual example, not evidence that $9.4 million arrived or remains available today.
SINTX Technologies (Nasdaq: SINT) made the distinction explicit in its 12 August 2026 registration filing: 1,268,135 new warrant shares at $2.14 could yield approximately $2.7 million on full cash exercise. Cashless exercise would yield no exercise payment. The amount describes a conditional financing route, rather than cash on the balance sheet.
Tonix Pharmaceuticals Holding (Nasdaq: TNXP) supplies a different example. Its 29 December 2025 prospectus supplement priced pre-funded warrants at $16.259, with $0.001 remaining payable per share. It also permitted net-share cashless exercise. Most of the purchase price belonged to the initial financing; later exercise could bring only nominal additional money, or none.
These examples explain terms disclosed on particular dates. They do not establish how many of those instruments remain outstanding, whether holders subsequently exercised, or the current funding position of any issuer. The listed securities identified here are the companies’ common shares, not the warrants themselves.
Interpretation: count two flows separately
The useful comparison has two columns: shares delivered and cash received. An exercise notice can affect the first without adding to the second. Neither column should silently stand in for the other.
A simplified hypothetical shows why. Assume a warrant permits a net exercise using the formula: underlying shares multiplied by the difference between a specified reference price and the exercise price, divided by that reference price. With 1,000 underlying shares, a $5 reference price and a $2 exercise price, the result is 600 shares: 1,000 × ($5 − $2) ÷ $5.
Hypothetical · net exercise
Shares without exercise cash
Shares delivered
1,000 × ($5 − $2) ÷ $5
The formula follows the structure in SINTX’s June 2026 warrant exhibit. Its actual reference-price definition depends on notice timing and specified market measures. Cashless exercise under that clause requires more than 90 days from the initial exercise date and unavailable resale registration or prospectus; the document also provides automatic cashless exercise at termination. The hypothetical assumes eligibility and ignores fractional-share complications. It is not a calculation for a current holder.
Under cash exercise of the hypothetical 1,000 underlying shares, the company would instead receive $2,000 and deliver 1,000 shares. Under the assumed net exercise, it delivers fewer shares but receives no exercise cash. Calling one result automatically better would require a valuation and funding assessment that this arithmetic does not supply.
Who could benefit?
Interpretation: A holder with a valid cashless right can receive the contractual net shares without supplying the exercise payment. Whether that is useful depends on eligibility, the formula and the value of the resulting security. It is not a promise of profit.
Cingulate and SINTX could receive additional working capital if eligible holders choose cash exercise. Their cited documents connect potential proceeds to development or corporate funding. The benefit occurs when money is received; its materiality depends on the amount relative to expenditure and other funding needs. A maximum exercise-proceeds figure is not a cash-runway estimate.
Tonix’s example instead shows the benefit of collecting almost all the price at issuance of a pre-funded instrument. Subsequent exercise should not be treated as another financing of the same size. The company’s original supplement linked intended proceeds to commercialisation, pipeline development and working capital. That intention does not establish what was ultimately spent or achieved.
Who’s at risk?
Interpretation: Existing common shareholders in all three companies face a change in percentage ownership when additional common shares are delivered, assuming their own holdings remain unchanged. Cashless settlement may deliver fewer shares than full cash exercise under the illustrated formula, but it does not make those delivered shares disappear from the denominator.
The funding risk is different. Cingulate or SINTX would not receive the illustrated cash-exercise proceeds if the relevant settlement were cashless. A business planning expenditure against that conditional money would need another source or a change in spending. This is a mechanism, not an assertion that either company has made that planning mistake.
For Tonix, the corresponding mistake would be counting the initial pre-funded purchase price again when shares are issued. Across all three examples, significance depends on actual exercises, remaining rights, available cash and spending over subsequent months. None of these links predicts a share-price fall.
Speculation: what would settle the funding question?
A later filing might show cash exercises, net settlements, expiry or amended terms. Each could change the remaining share claims and prospective cash differently. Without that reconciliation, neither the face value of the warrants nor a registration headline provides a reliable funding forecast.
The next useful evidence is a bridge from opening warrants to exercises, cancellations and closing balances, paired with cash proceeds actually received. Registration status, exercise conditions and subsequent amendments complete the picture. Put the new shares in the denominator, then check whether any new money entered the bank.
Sources checked 30 October 2026. This article explains financing disclosures and is for information, not investment advice.
Photo by Ivan S on Pexels. Laboratory glassware containing coloured liquids.